This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Sponsored by Takeda

About this trial

Last updated 7 months ago

Study ID

TAK-062-2001

Status

Completed

Type

Interventional

Phase

Phase 2

Placebo

Yes

Accepting

18-75 Years
12+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 8 months ago

What is this trial about?

The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.

What are the participation requirements?

Yes

Inclusion Criteria

Both men and women can take part.
Must be 12 years and older. Adolescents aged 12 to 17 years, inclusive, will be enrolled in Cohort 2 of the study.
Must have biopsy-confirmed Celiac Disease.
Must be attempting to maintain a gluten-free diet for at least 12 months.

Additional entry criteria will be discussed with the study doctor.

Locations

Location

Status

For more information, view the full study details:

NCT053539852020-005438-14